Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register for free online access

Click here to sign up for SAGE Journal Email Alerts today!
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1087057105278927v1
10/8/788    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mangru, S.
Right arrow Articles by Kodukula, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mangru, S.
Right arrow Articles by Kodukula, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Integrated Bioassays in Microfluidic Devices: Botulinum Toxin Assays

Shakuntala Mangru

Bryan L. Bentz

Timothy J. Davis

Nitin Desai

Paul J. Stabile

Sarnoff Corporation, 201 Washington Road, Princeton, NJ

James J. Schmidt

Charles B. Millard

Sina Bavari

Division of Toxinology and Aerobiology, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD

Krishna Kodukula

Sarnoff Corporation, 201 Washington Road, Princeton, NJ

A microfluidic assay was developed for screening botulinum neurotoxin serotype A (BoNT-A) by using a fluorescent resonance energy transfer (FRET) assay. Molded silicone microdevices with integral valves, pumps, and reagent reservoirs were designed and fabricated. 1-4Electrical and pneumatic control hardwarewere constructed, and softwarewaswritten to automate the assay protocol and data acquisition. Detection was accomplished by fluorescence microscopy. The system was validated with a peptide inhibitor, running 2 parallel assays, as a feasibility demonstration. The small footprint of each bioreactor cell (0.5cm2) and scalable fluidic architecture enabled many parallel assays on a single chip. The chip is programmable to run a dilution series in each lane, generating concentration-response data for multiple inhibitors. The assay results showed good agreement with the corresponding experiments done at a macroscale level. Although the system has been developed for BoNT-A screening, awide variety of assays can be performed on themicrofluidic chipwith little or nomodification.

Key Words: botulinum neurotoxin serotype A • bioassay • microfluidic devices • detection

This version was published on December 1, 2005

Journal of Biomolecular Screening, Vol. 10, No. 8, 788-794 (2005)
DOI: 10.1177/1087057105278927
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Appl. Environ. Microbiol.Home page
H. B. Hines, A. D. Kim, R. G. Stafford, S. S. Badie, E. E. Brueggeman, D. J. Newman, and J. J. Schmidt
Use of a Recombinant Fluorescent Substrate with Cleavage Sites for All Botulinum Neurotoxins in High-Throughput Screening of Natural Product Extracts for Inhibitors of Serotypes A, B, and E
Appl. Envir. Microbiol., February 1, 2008; 74(3): 653 - 659.
[Abstract] [Full Text] [PDF]